Lai Wang Sells 259 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

Key Points

• Lai Wang, an insider at BeOne Medicines, recently sold 259 shares of the company's stock for a total of $78,995.00, decreasing their position by 0.03% to 1,023,529 shares.
• BeOne Medicines has faced a negative net margin of 9.40% and analysts predict it will report earnings per share of -5.82 for the current year.
• The firm received multiple analyst upgrades, with Wall Street Zen raising its rating from "hold" to "buy" and new price targets set between $330.00 and $349.00 by various brokerages.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 259 shares of BeOne Medicines stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $305.00, for a total value of $78,995.00. Following the completion of the sale, the insider directly owned 1,023,529 shares in the company, valued at approximately $312,176,345. This represents a 0.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Lai Wang also recently made the following trade(s):

• On Tuesday, July 29th, Lai Wang sold 4,041 shares of BeOne Medicines stock. The stock was sold at an average price of $302.49, for a total value of $1,222,362.09.
• On Friday, July 18th, Lai Wang sold 700 shares of BeOne Medicines stock. The stock was sold at an average price of $300.00, for a total value of $210,000.00.
• On Monday, June 23rd, Lai Wang sold 1,028 shares of BeOne Medicines stock. The stock was sold at an average price of $260.00, for a total value of $267,280.00.
• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total value of $118,143.90.
• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The stock was sold at an average price of $266.40, for a total value of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total value of $353,850.78.

BeOne Medicines Price Performance

ONC traded up $1.19 during trading on Thursday, hitting $301.13. 503,014 shares of the stock traded hands, compared to its average volume of 438,001. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $155.75 and a twelve month high of $308.87. The firm has a market cap of $33.00 billion, a P/E ratio of -80.95 and a beta of 0.28. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. The business's 50 day moving average is $261.59.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ONC. Wall Street Zen upgraded BeOne Medicines from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. TD Securities restated a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a report on Thursday, April 24th. Royal Bank Of Canada boosted their price target on BeOne Medicines from $311.00 to $349.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Finally, Morgan Stanley boosted their price target on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, June 27th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, BeOne Medicines has an average rating of "Buy" and a consensus price target of $327.56.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in BeOne Medicines in the second quarter valued at $28,000. Farther Finance Advisors LLC acquired a new stake in BeOne Medicines in the second quarter valued at $39,000. Signaturefd LLC acquired a new stake in BeOne Medicines in the second quarter valued at $49,000. Parallel Advisors LLC bought a new stake in BeOne Medicines during the second quarter valued at $59,000. Finally, FNY Investment Advisers LLC bought a new stake in BeOne Medicines during the second quarter valued at $121,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.